Phospholamban: A promising therapeutic target in heart failure?

Cardiovascular Drugs and Therapy

Volumn 15, Issue 5, 2001, Pages 387-396

  Schmidt, Albrecht G ^a   Edes, Istvan ^b   Kranias, Evangelia G ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Calcium cycling; Heart; Phospholamban; Sarcoplasmic reticulum

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM ION; INOTROPIC AGENT; PHOSPHOLAMBAN; REGULATOR PROTEIN;

BETA ADRENERGIC STIMULATION; CALCIUM TRANSPORT; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; EXCITATION CONTRACTION COUPLING; HEART CONTRACTION; HEART DILATATION; HEART DISEASE; HEART EXCITATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; INOTROPISM; PRIORITY JOURNAL; PROTEIN INTERACTION; SARCOPLASMIC RETICULUM; TREATMENT PLANNING;

ANIMALS; CALCIUM-BINDING PROTEINS; CALCIUM-TRANSPORTING ATPASES; CARDIOMYOPATHY, DILATED; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 0035700695     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013381204658     Document Type: Conference Paper

References (77)

1. Pharmacology of the cardiac sarcoplasmic reticulum calcium ATPase-phospholamban interaction
2. Heart failure: Future treatment approaches
3. Molecular inotropy: A future approach to the treatment of heart failure?
4. Cardiac remodeling - Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling
5. Why does the myocardium fail? Insights from basic science
6. Alterations of calcium-regulatory proteins in heart failure
7. Animal models of human cardiovascular disease, heart failure and hypertrophy
8. Cellular and molecular aspects of contractile dysfunction in heart failure
9. Abnormalities of calcium cycling in the hypertrophied and failing heart
10. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium
11. Ca transport during contraction and relaxation in mammalian ventricular muscle
12. Phospholamban: A protein coming of age
13. Phospholamban: Protein structure, mechanism of action, and role in cardiac function
14. Sites of regulatory interaction between calcium ATPases and phospholamban
15. Amino acids Glu2 to Ile18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca(2+)-ATPase of sarcoplasmic reticulum
16. Molecular mechanism of regulation of Ca2+ pump ATPase by phospholamban in cardiac sarcoplasmic reticulum. Effects of synthetic phospholamban peptides on Ca2+ pump ATPase
17. Phospholamban regulates the Ca2+-ATPase through intramembrane interactions
18. Phospholamban domain Ib mutations influence functional interactions with the Ca2+-ATPase isoform of cardiac sarcoplasmic reticulum
19. Cardiac-specific overexpression of a superinhibitory pentameric phospholamban mutant enhances inhibition of cardiac function in vivo
20. Sites of regulatory interaction between calcium ATPases and phospholamban
21. Sarcoplasmic reticulum Ca2+ transport
22. Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart
23. The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme
24. Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart
25. Genetically engineered mice: Model systems for left ventricular failure
26. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice
27. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation
28. Effect of ablation of phospholamban on dynamics of cardiac myocyte contraction and intracellular Ca2+
29. Regulatory effects of phospholamban on cardiac function in intact mice
30. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency
31. Maximal inhibition of SERCA2 Ca(2+) affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban
32. Invasive hemodynamics and force-frequency relationships in open-versus closed-chest mice
33. Modulation of force-frequency relation by phospholamban in genetically engineered mice
34. Phospholamban gene dosage effects in the mammalian heart
35. Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy
36. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure
37. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy
38. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure
39. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction
40. Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure
41. Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium
42. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure
43. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy
44. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts
45. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts
46. Is the failing heart energy depleted?
47. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure
48. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts
49. Increased expression of cardiac phosphatases in patients with end-stage heart failure
50. Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation
51. Origin of contractile dysfunction in heart failure: Calcium cycling versus myofilaments
52. Distinguishing mechanisms from markers of cardiac contractile dysfunction: More than 1 way to skin the cat of heart failure
53. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality
54. Of phospholamban, mice, and humans with heart failure
55. Phospholamban inhibitory function is activated by depolymerization
56. Functional co-expression of the canine cardiac Ca2+ pump and phospholamban in Spodoptera frugiperda (Sf21) cells reveals new insights on ATPase regulation
57. The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility
58. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy
59. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation
60. Re-evaluating sarcoplasmic reticulum function in heart failure
61. Pathogenesis of dilated cardiomyopathy: Molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice
62. Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts
63. Phospholamban deficiency does not compromise exercise capacity
64. Stimulation of sarcoplasmic reticulum Ca(2+)-ATPase by gingerol analogues
65. Interactions of 6-gingerol and ellagic acid with the cardiac sarcoplasmic reticulum Ca2+-ATPase
66. Plakortides, novel cyclic peroxides from the sponge Plakortis halichondrioides: Activators of cardiac SR-CA(2+)-pumping ATPase
67. Mechanism of action of sarcoplasmic reticulum calcium-uptake activators - Discrimination between sarco(endo)plasmic reticulum Ca2+ ATPase and phospholamban interaction
68. Dissociation of phospholamban regulation of cardiac sarcoplasmic reticulum Ca2+ATPase by quercetin
69. Relationship between phospholamban and nucleotide activation of cardiac sarcoplasmic reticulum Ca2+ adenosinetriphosphatase
70. Nucleotide mimetics reverse phospholamban regulation in cardiac sarcoplasmic reticulum
71. Reversal of phospholamban-induced inhibition of cardiac sarcoplasmic reticulum Ca(2+)-ATPase by tannin
72. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure
73. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase
74. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a
75. Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: Comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter
76. Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility